Products Affected - Description
Hydralazine injection, Akorn
20 mg/mL, 1 mL vial, 10 count (NDC 17478-0934-01) - discontinued
20 mg/mL, 1 mL vial, 25 count (NDC 17478-0934-15)
Hydralazine injection, American Regent
20 mg/mL, 1 mL vial, 25 count (NDC 00517-0901-25)
Reason for the Shortage
- Akorn did not provide a reason for the hydralazine injection on shortage.
- American Regent has hydralazine injection on shortage due to manufacturing delays.
- Fresenius Kabi has hydralazine injection available.
- X-Gen launched hydralazine injection in September 2015.
Hydralazine injection, Fresenius Kabi
20 mg/mL, 1 mL vial, 25 count (NDC 63323-0614-01)
Hydralazine injection, X-Gen
20 mg/mL, 1 mL vial, 25 count (NDC 39822-0500-04)
Estimated Resupply Dates
- Akorn has hydralazine 20 mg/mL 1 mL vials in 25 count available with expiration dates of July or August 2017.
- American Regent has hydralazine 20 mg/mL 1 mL vials on back order and the company cannot estimate a release date.
November 18, September 21, August 16, May 24, April 20, March 30 and 11, January 20, 2016; December 22, November 3, September 28 and 9, June 29, May 21, April 30, March 23, February 17, January 27 and 16, 2015; December 12, November 11, October 2, September 12, 2014, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins